Prevalence of SARS-CoV-2 Omicron Sublineages and Spike Protein Mutations Conferring Resistance against Monoclonal Antibodies in a Swedish Cohort during 2022–2023

Monoclonal antibodies (mAbs) are an important treatment option for COVID-19 caused by SARS-CoV-2, especially in immunosuppressed patients. However, this treatment option can become ineffective due to mutations in the SARS-CoV-2 genome, mainly in the receptor binding domain (RBD) of the spike (S) pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Haars, Jonathan, Palanisamy, Navaneethan, Wallin, Frans, Mölling, Paula, Lindh, Johan, Sundqvist, Martin, Ellström, Patrik, Kaden, René, Lennerstrand, Johan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10609123/
https://www.ncbi.nlm.nih.gov/pubmed/37894075
http://dx.doi.org/10.3390/microorganisms11102417

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10609123/
https://www.ncbi.nlm.nih.gov/pubmed/37894075
http://dx.doi.org/10.3390/microorganisms11102417

Ejemplares similares